150
Participants
Start Date
September 8, 2021
Primary Completion Date
September 30, 2026
Study Completion Date
March 31, 2027
Dupilumab
anti-IL4 receptor antagonist
Placebo
Placebo for Dupilumab (packaged/administered the same as the active drug)
RECRUITING
Montefiore Einstein Clinical Research Center, The Bronx
RECRUITING
University of Pennsylvania, Philadelphia
RECRUITING
MetroHealth System, Cleveland
RECRUITING
Henry Ford Health System, Detroit
RECRUITING
Boston Children's Hospital, Boston
RECRUITING
Brigham and Women's Hospital, Boston
Collaborators (1)
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Regeneron Pharmaceuticals
INDUSTRY
HealthBeacon Plc
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY
Sanofi
INDUSTRY
Boston Children's Hospital
OTHER